Cardiac rehabilitation agent
AssigneeOtsuka Pharmaceutical Factory, Inc.
InventorsKazuo Ichihara, Hiroomi Yokoyama
Life of this patent
Estimating the term…
Abstract
This invention provides a cardiac rehabilitation agent comprising at least one species of the class consisting of purine nucleoside and purine nucleotide, e.g. a composition comprising inosine, cytidine, uridine, a salt of guanosine 5'-monophosphate, and thymidine in a molar ratio of 4:4:3:4:1. The cardiac rehabilitation agent of this invention is characterized by excellent cardiac function-restorative activity and no risk of side effect.
Claims8
A method of restoring cardiac function following ischemia-reperfusion comprising administering to a subject in need thereof a pharmaceutically effective amount of a cardiac rehabilitation composition consisting essentially of:
- (i) at least one purine nucleoside, with the proviso that the purine nucleoside is not adenosine, and
- (ii) at least one purine nucleotide or salt thereof;
- or
- (i) at least one purine nucleoside, with the proviso that the purine nucleoside is not adenosine, and
- (ii) at least one purine nucleotide or salt thereof and
- (iii) at least one pyrimidine nucleoside.
A method of restoring cardiac function following ischemia-reperfusion comprising administering to a subject in need thereof a pharmaceutically effective amount of a cardiac rehabilitation composition consisting essentially of inosine, cytidine, uridine, guanosine 5'-monophosphate or salt thereof, and thymidine.
Dependencies are inferred from the claim text.